ReachMD
Be part of the knowledge.™Spotlight on Non-Small Cell Lung Cancer
Up to 85 percent of all lung cancer cases are characterized as non-small cell lung cancer, underscoring the importance of keeping up to date on the latest diagnostic and treatment advances. That’s why this Spotlight on Non-Small Cell Lung Cancer brings together leading oncologists and other allied healthcare professionals to discuss key research updates and other novel insights.
AEGEAN Trial: The Role of Perioperative Durvalumab in NSCLC
Project Oncology®AEGEAN Trial: The Role of Perioperative Durvalumab in NSCLC
Novel Immune Checkpoint Strategies in Non-Small Cell Lung Cancer Care
Project Oncology®Novel Immune Checkpoint Strategies in Non-Small Cell Lung Cancer Care
Treating Patients with NSCLC: Decision-Making and Surgical Considerations
Project Oncology®Treating Patients with NSCLC: Decision-Making and Surgical Considerations
NSCLC Care: Evaluating Durvalumab in the First-Line Setting
Project Oncology®NSCLC Care: Evaluating Durvalumab in the First-Line Setting
The Evolving Landscape of Targeted Therapies for Non-Small Cell Lung Cancer
Project Oncology®The Evolving Landscape of Targeted Therapies for Non-Small Cell Lung Cancer
Antibody-Drug Conjugates: An Emerging Approach in NSCLC Treatment
Project Oncology®Antibody-Drug Conjugates: An Emerging Approach in NSCLC Treatment
targetedonc.com
02/16/2024- uclahealth.org
01/12/2024
- scienmag.com
01/08/2024
- sciencedaily.com
01/04/2024
- targetedonc.com
12/28/2023
- targetedonc.com
12/28/2023